129 related articles for article (PubMed ID: 38245817)
1. Citric acid promotes SPARC release in pancreatic cancer cells and inhibits the progression of pancreatic tumors in mice on a high-fat diet.
Xiao G; Wei Y; Xie R; Tsang Y; Gu J; Shen D; Ding M; Yuan J; Xu D; Fei J
FEBS J; 2024 Apr; 291(8):1699-1718. PubMed ID: 38245817
[TBL] [Abstract][Full Text] [Related]
2. SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.
Kaleağasıoğlu F; Berger MR
World J Gastroenterol; 2014 Oct; 20(40):14747-59. PubMed ID: 25356037
[TBL] [Abstract][Full Text] [Related]
3. Reduction of SPARC protects mice against NLRP3 inflammasome activation and obesity.
Ryu S; Spadaro O; Sidorov S; Lee AH; Caprio S; Morrison C; Smith SR; Ravussin E; Shchukina I; Artyomov MN; Youm YH; Dixit VD
J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37781916
[TBL] [Abstract][Full Text] [Related]
4. SPARC is required for the maintenance of glucose homeostasis and insulin secretion in mice.
Atorrasagasti C; Onorato A; Gimeno ML; Andreone L; Garcia M; Malvicini M; Fiore E; Bayo J; Perone MJ; Mazzolini GD
Clin Sci (Lond); 2019 Jan; 133(2):351-365. PubMed ID: 30626728
[TBL] [Abstract][Full Text] [Related]
5. Secreted protein acidic and rich in cysteine inhibits the growth of human pancreatic cancer cells with G1 arrest induction.
Mao Z; Ma X; Fan X; Cui L; Zhu T; Qu J; Zhang J; Wang X
Tumour Biol; 2014 Oct; 35(10):10185-93. PubMed ID: 25027401
[TBL] [Abstract][Full Text] [Related]
6. Secreted protein acidic and rich in cysteine enhances the chemosensitivity of pancreatic cancer cells to gemcitabine.
Fan X; Mao Z; Ma X; Cui L; Qu J; Lv L; Dang S; Wang X; Zhang J
Tumour Biol; 2016 Feb; 37(2):2267-73. PubMed ID: 26358255
[TBL] [Abstract][Full Text] [Related]
7. SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer.
Ramu I; Buchholz SM; Patzak MS; Goetze RG; Singh SK; Richards FM; Jodrell DI; Sipos B; Ströbel P; Ellenrieder V; Hessmann E; Neesse A
EBioMedicine; 2019 Oct; 48():161-168. PubMed ID: 31597597
[TBL] [Abstract][Full Text] [Related]
8. Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater.
Prenzel KL; Warnecke-Eberz U; Xi H; Brabender J; Baldus SE; Bollschweiler E; Gutschow CA; Hölscher AH; Schneider PM
Oncol Rep; 2006 May; 15(5):1397-401. PubMed ID: 16596217
[TBL] [Abstract][Full Text] [Related]
9. The role of SPARC (secreted protein acidic and rich in cysteine) in the pathogenesis of obesity, type 2 diabetes, and non-alcoholic fatty liver disease.
Atorrasagasti C; Onorato AM; Mazzolini G
J Physiol Biochem; 2023 Nov; 79(4):815-831. PubMed ID: 36018492
[TBL] [Abstract][Full Text] [Related]
10. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions.
Sato N; Fukushima N; Maehara N; Matsubayashi H; Koopmann J; Su GH; Hruban RH; Goggins M
Oncogene; 2003 Aug; 22(32):5021-30. PubMed ID: 12902985
[TBL] [Abstract][Full Text] [Related]
11. SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.
Hidalgo M; Plaza C; Musteanu M; Illei P; Brachmann CB; Heise C; Pierce D; Lopez-Casas PP; Menendez C; Tabernero J; Romano A; Wei X; Lopez-Rios F; Von Hoff DD
Clin Cancer Res; 2015 Nov; 21(21):4811-8. PubMed ID: 26169969
[TBL] [Abstract][Full Text] [Related]
12. SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer.
Vaz J; Ansari D; Sasor A; Andersson R
Pancreas; 2015 Oct; 44(7):1024-35. PubMed ID: 26335014
[TBL] [Abstract][Full Text] [Related]
13. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis.
Puolakkainen PA; Brekken RA; Muneer S; Sage EH
Mol Cancer Res; 2004 Apr; 2(4):215-24. PubMed ID: 15140943
[TBL] [Abstract][Full Text] [Related]
14. YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation.
Xiao Y; Zhang H; Ma Q; Huang R; Lu J; Liang X; Liu X; Zhang Z; Yu L; Pang J; Zhou L; Liu T; Wu H; Liang Z
Cancer Lett; 2019 Oct; 462():51-60. PubMed ID: 31352078
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of secreted protein acidic and rich in cysteine in patients with solid tumors.
Ma Y; Chen H; Ma H; Yao Z; Hu J; Ma J; Zhang X; Chen G; Liu Y
Saudi Med J; 2019 Aug; 40(8):755-765. PubMed ID: 31423511
[TBL] [Abstract][Full Text] [Related]
16. Fibronectin acts as a molecular switch to determine SPARC function in pancreatic cancer.
Munasinghe A; Malik K; Mohamedi F; Moaraf S; Kocher H; Jones L; Hill NJ
Cancer Lett; 2020 May; 477():88-96. PubMed ID: 32113990
[TBL] [Abstract][Full Text] [Related]
17. A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo.
Rahman M; Chan AP; Tang M; Tai IT
PLoS One; 2011; 6(11):e26390. PubMed ID: 22069448
[TBL] [Abstract][Full Text] [Related]
18. The 'SPARC' of life: Analysis of the role of osteonectin/SPARC in pancreatic cancer (Review).
Rossi MK; Gnanamony M; Gondi CS
Int J Oncol; 2016 May; 48(5):1765-71. PubMed ID: 26983777
[TBL] [Abstract][Full Text] [Related]
19. Stromal expression of SPARC in pancreatic adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Cros J; Faivre S; Hammel P; Raymond E
Cancer Metastasis Rev; 2013 Dec; 32(3-4):585-602. PubMed ID: 23690170
[TBL] [Abstract][Full Text] [Related]
20. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts.
Kim H; Samuel S; Lopez-Casas P; Grizzle W; Hidalgo M; Kovar J; Oelschlager D; Zinn K; Warram J; Buchsbaum D
Mol Cancer Ther; 2016 Apr; 15(4):680-8. PubMed ID: 26832793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
